Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

scientific article

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1007/S40273-017-0528-Y
P932PMC publication ID5684255
P698PubMed publication ID28656543

P50authorJos KleijnenQ28037365
Nasuh BuyukkaramikliQ61092778
Janine RossQ63373125
Nigel ArmstrongQ92354906
Gill WorthyQ101239876
P2093author name stringMaiwenn J Al
Fiona J Clay
Hedwig M Blommestein
Rob Riemsma
Johan Severens
P2860cites workThe European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyQ29615701
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialQ29620687
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialQ29620917
Disparities in gastric cancer chemotherapy between the East and WestQ36472210
Health state utilities for metastatic breast cancerQ36591214
Health state utilities for non small cell lung cancerQ36963976
Elicitation of health state utilities in metastatic renal cell carcinomaQ37708305
Geographic differences in approach to advanced gastric cancer: Is there a standard approach?Q38114265
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Q42608504
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaQ44177579
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400Q44754243
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapyQ44923328
Race and ethnicity correlate with survival in patients with gastric adenocarcinomaQ47633003
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialQ48117450
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.Q53384216
Costs of palliative care in the community, in hospitals and in hospices in the UKQ56562451
P275copyright licenseCreative Commons Attribution-NonCommercialQ6936496
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectadenocarcinomaQ356033
monoclonal antibodyQ422248
stomach neoplasmQ4335552
esophageal neoplasmQ56014520
antineoplastic combined chemotherapy protocolsQ66764603
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)1211-1221
P577publication date2017-12-01
P1433published inPharmacoEconomicsQ7180778
P1476titleRamucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
P478volume35

Reverse relations

cites work (P2860)
Q99585277Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials
Q94606068Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
Q94452251Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
Q90470975Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
Q33806813Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
Q57106177Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Q64944976Value of information analysis in telehealth for chronic heart failure management.
Q55210410Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Search more.